Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Breye Therapeutics has raised $4.1M in total funding. The most recent round was Seed. The last funding was announced in November 2022.
Breye Therapeutics's investors include Novo Holdings, BioInnovation Institute, Sound Bioventures, Vaekstfonden, Innovation Fund Denmark.
Breye Therapeutics is headquartered in Hørsholm, Denmark.
Breye Therapeutics, a biopharmaceutical firm that provide cutting-edge oral treatments for the management of retinal vascular diseases.
Breye Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Breye Therapeutics — Funding & Investors." VCBacked, November 10, 2022, https://www.vcbacked.co/company/breye-therapeutics. Accessed August 8, 2026.
VCBacked. (2022). Breye Therapeutics — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/breye-therapeutics
{{cite web |title=Breye Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/breye-therapeutics |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated